Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT).


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
14 Nov 2019
Historique:
received: 19 07 2019
accepted: 10 10 2019
entrez: 22 11 2019
pubmed: 22 11 2019
medline: 22 11 2019
Statut: epublish

Résumé

Small molecules that inhibit the metabolic enzyme NAMPT have emerged as potential therapeutics in oncology. As part of our effort in this area, we took a scaffold morphing approach and identified 3-pyridyl azetidine ureas as a potent NAMPT inhibiting motif. We explored the SAR of this series, including 5 and 6 amino pyridines, using a convergent synthetic strategy. This lead optimization campaign yielded multiple compounds with excellent in vitro potency and good ADME properties that culminated in compound

Identifiants

pubmed: 31749905
doi: 10.1021/acsmedchemlett.9b00325
pmc: PMC6862340
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1524-1529

Informations de copyright

Copyright © 2019 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare the following competing financial interest(s): The authors were all employees of the Novartis Institutes for Biomedical Research during the time when this work was completed.

Références

Toxicol Sci. 2015 Mar;144(1):163-72
pubmed: 25505128
Chem Biol. 2013 Nov 21;20(11):1307-8
pubmed: 24267273
J Med Chem. 2013 Aug 22;56(16):6279-96
pubmed: 23679915
J Immunol. 2008 Oct 1;181(7):4685-95
pubmed: 18802071
ACS Med Chem Lett. 2018 Jun 28;9(8):838-842
pubmed: 30128077
J Biol Chem. 2004 Dec 3;279(49):50754-63
pubmed: 15381699
Annu Rev Nutr. 2008;28:115-30
pubmed: 18429699
Toxicol Mech Methods. 2015 Mar;25(3):201-11
pubmed: 25894564
Curr Drug Targets. 2013 Jun 1;14(6):637-43
pubmed: 23531116
Bioorg Med Chem Lett. 2013 Jun 15;23(12):3531-8
pubmed: 23668988
Chembiochem. 2014 May 26;15(8):1121-30
pubmed: 24797455
Trends Biochem Sci. 2007 Jan;32(1):12-9
pubmed: 17161604
Bioorg Med Chem Lett. 2018 Feb 1;28(3):365-370
pubmed: 29275937
Pharmacol Ther. 2015 Jul;151:16-31
pubmed: 25709099
J Med Chem. 1996 Feb 2;39(3):625-56
pubmed: 8576904

Auteurs

Daniel S Palacios (DS)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Erik L Meredith (EL)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Toshio Kawanami (T)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Christopher M Adams (CM)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Xin Chen (X)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Veronique Darsigny (V)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Mark Palermo (M)

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Daniel Baird (D)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Elizabeth L George (EL)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Chantale Guy (C)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Jeffrey Hewett (J)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Laryssa Tierney (L)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Sachin Thigale (S)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Louis Wang (L)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Wilhelm A Weihofen (WA)

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

Classifications MeSH